Tin tức & Cập nhật
Lọc theo Chuyên ngành:
SGLT2i beats DPP4i at reducing cardiovascular disease in type 2 diabetes
18 May 2022
Treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i) leads to lower rates of cardiovascular disease (CVD) events in patients with type 2 diabetes mellitus (T2DM) than does dipeptidyl peptidase-4 inhibitors (DPP4i), reports a recent Japan study.
SGLT2i beats DPP4i at reducing cardiovascular disease in type 2 diabetes
18 May 2022Musculoskeletal pain common in T2D but does not influence treatment goals
10 May 2022
Musculoskeletal pain is a common coexisting symptom in patients with type 2 diabetes (T2D), with most patients having knee or lower back pain, a study reports. However, despite the major disability burden associated with these types of pain, it does not seem to get in the way of achieving treatment targets.